

1 **Species-specific bacterial detector for fast pathogen diagnosis of severe pneumonia**
2 **patients in the intensive care unit**

3 Yan Wang^{1#}, Xiaohui Liang^{2#}, Yuqian Jiang², Danjiang Dong¹, Cong Zhang²,
4 Tianqiang Song², Ming Chen¹, Yong You¹, Han Liu³, Min Ge⁴, Haibin Dai⁵, Fengchan
5 Xi⁶, Wanqing Zhou⁷, Jian-Qun Chen², Qiang Wang^{2*}, Qihan Chen^{2,8*}, Wenkui Yu^{1,8*}

6

7 1 Department of Critical Care Medicine, Nanjing Drum Tower Hospital, The Affiliated
8 Hospital of Nanjing University Medical School, Nanjing, Jiangsu 21008, China.

9 2 The State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences,
10 Nanjing University, Nanjing, Jiangsu 210023, China.

11 3 Department of Critical Care Medicine, Nanjing First Hospital, Nanjing Medical
12 University, Nanjing, Jiangsu 210006, China.

13 4 Department of Cardiothoracic Surgery Intensive Care Unit, Nanjing Drum Tower
14 Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing,
15 Jiangsu 210008, China.

16 5 Department of Neurosurgery Intensive Care Unit, Nanjing Drum Tower Hospital, The
17 Affiliated Hospital of Nanjing University Medical School, Nanjing, Jiangsu 210008,
18 China.

19 6 Research Institute of General Surgery, Affiliated Jinling Hospital, Medical School of
20 Nanjing University, Nanjing, Jiangsu 210002, China.

21 7 Department of Laboratory Medicine, Nanjing Drum Tower Hospital, The Affiliated
22 Hospital of Nanjing University Medical School, Nanjing University, Nanjing 210008,

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

23 China.

24 8 Medical School of Nanjing University, Nanjing, Jiangsu 210093, China.

25 #These authors share first author

26 *Corresponding author

27 **Corresponding Author:**

28 Wenkui Yu, Ph.D., M.D.

29 Department of Critical Care Medicine, Nanjing Drum Tower Hospital

30 Nanjing, Jiangsu 21008, China

31 Phone: +86 13701582986

32 yudrnj2@163.com

33

34 Qihan Chen, Ph.D.

35 School of Life Sciences, Nanjing University

36 Nanjing, Jiangsu 210023, China

37 Phone: +86 13236592587

38 chenqihan@nju.edu.cn

39

40 Qiang Wang, Ph.D.

41 School of Life Sciences, Nanjing University

42 Nanjing, Jiangsu 210023, China

43 Phone: +86 13382014346

44 wangq@nju.edu.cn.

45 **Abstract**

46 Rapid diagnosis of pathogens is the cornerstone of appropriate therapy and is also a
47 great challenge to be overcome. Although NGS and some other PCR-based pathogen
48 detection methods were applied to improve the speed and accuracy of clinical diagnosis,
49 it was still a long way from the clinical needs of rapid and accurate diagnostic therapy
50 in the intensive care unit (ICU). In this study, we aimed at developing a new rapid
51 diagnostic tool, Species-Specific Bacterial Detector (SSBD), to evaluate the existence
52 and quantification of 10 most usual pathogenic bacteria in ICU in 4 hours. Briefly, the
53 species-specific genome fragments of each bacterium were identified by our algorithm
54 using 1791 microbe genomes from 232 species and then used to combine with
55 CRISPR/Cas12 to establish diagnosis tools. Based on the tests of 77 samples, SSBD
56 demonstrated 100% sensitivity and 87% specificity compared with conventional
57 culture test (CCT). Later on, an interventional random-grouped study was applied to
58 evaluate the clinical benefits of SSBD. Briefly, SSBD demonstrated more accurate and
59 faster diagnosis results and led to earlier antibiotics adjustment than CCT. Based on the
60 results acquired by SSBD, cultivation results could deviate from the real pathogenic
61 situation with polymicrobial infections. In addition, nosocomial infections were found
62 widely in ICU, which should deserve more attention.

63

64 **Keywords:** Diagnosis, Pathogen, Severe pneumonia, Intensive care unit, Antimicrobial
65 therapy

66

67 **1. Introduction**

68 Sepsis is associated with high morbidity and mortality [1]. Adequate antibiotic therapy
69 in time could decrease mortality and reduce the length of stay in ICU for patients with
70 sepsis or septic shock [2-5]. As reported in the previous study, the mortality rate of
71 patients increased approximately 7.6% for every hour delayed [3]. Therefore, rapid
72 diagnosis of pathogenic microorganisms is crucial for shortening the time of empirical
73 antibiotic therapy and improving the prognosis of patients with sepsis.

74 Conventional culture test (CCT) is the most commonly used and golden standard
75 identification method of pathogenic microorganisms in most countries. However, it
76 showed two critical limitations: long time-consuming (2 to 5 days) and low sensitivity
77 (30-50%), which limited the application of this method in the ICU [6, 7]. To overcome
78 this bottleneck, several new tools were developed and showed significant improvement
79 in time consumption and accuracy. Recently, next-generation sequencing (NGS)
80 technology was applied to acquire the entire information of microorganisms and
81 demonstrated great ability in diagnosing rare pathogens. However, the whole process
82 still needs at least 2 days for the full diagnostic report with high cost [8, 9]. On the other
83 hand, NGS provided too much information about microorganisms but only semi-
84 quantification of pathogens, which was hard for most clinical doctors to extract the most
85 important information to determine antibiotic usage. Other new emerging detection
86 techniques designed by BioFire and Curetis are much superior in detection time than
87 these above. However, its original principle was based on nucleotide diversity of
88 conserved genes among species, which could not satisfy the application in the ICU due

89 to potential false-positive results [10-12]. Therefore, a unique diagnosis tool aimed at
90 faster and more accurate pathogen identification in the ICU was still a great challenge.

91 In this study, we aimed to design a simple and convenient diagnosis tool for sepsis
92 patients in the ICU, which covered the most common pathogenic bacteria and
93 completed the detection process in the shortest possible time with low cost and
94 minimum instrument requirements. A clinical trial with two stages was applied to
95 evaluate the accuracy of the tool and the clinical benefits.

96

97 **2. Materials and Methods**

98 **2.1. Study design**

99 The full study design was shown in **Fig 1**. In the discovery stage, we screened species
100 specific DNA-tags of 10 epidemic pathogenic bacteria in the ICU. In the training stage,
101 we optimized reaction conditions and sample preparation process, including detection
102 concentration limitation, DNA purification, and incubation time of the CRISPR/Cas12a
103 reaction. The finalized experiment operating procedure of SSBD was used in the
104 subsequent stages (detailed protocol was shown in Supplementary Materials).

105 In validation stage I, 77 specimens of bronchoalveolar lavage fluid (BALF) directly
106 acquired from patients in ICU were finally detected by SSBD to confirm the specificity
107 and sensitivity of SSBD compared to CCT results. Some of the samples were sent to
108 NGS technology, providing additional references.

109 After the stability and accuracy of SSBD were thoroughly evaluated, the validation
110 stage II, a preliminary clinical intervention experiment, was launched to verify the

111 clinical application of the SSBD.

112 **2.2. Ethics Approval**

113 We acquired the ethics approval (2019-197-01) from the ethics committee of Nanjing
114 Drum Tower Hospital Affiliated to Nanjing University Medical School in July 2019,
115 registered and posted the complete research protocol, informed consent, subject
116 materials, case report form, researcher manual, the introduction of main researchers and
117 other information in Chinese. Later on, this study was registered in English at
118 ClinicalTrilas.gov (NCT04178382) in November 2019.

119 **2.3. Screening species-specific DNA tags**

120 We designed a process to find the species-specific DNA tags according to the basic
121 principle, intraspecies-conserved and interspecies-specific sequences (illustrated in **Fig**
122 **2A**). 1791 high-quality genomes of 232 microorganism species from the public
123 databases were included in the screening process. To accelerate the screening process,
124 we developed a linear comparison algorithm instead of comparing every two genomes,
125 which could save more than 90% of calculation time cost (**S1 Fig**). 10 species of
126 bacteria were selected as targets for subsequent detecting process, including
127 *Acinetobacter baumannii* (*A. baumannii*), *Escherichia coli* (*E. coli*), *Klebsiella*
128 *pneumoniae* (*K. pneumoniae*), *Pseudomonas aeruginosa* (*P. aeruginosa*),
129 *Stenotrophomonas maltophilia* (*S. maltophilia*), *Staphylococcus aureus* (*S. aureus*),
130 *Staphylococcus epidermidis* (*S. epidermidis*), *Staphylococcus capitis* (*S. capitis*),
131 *Enterococcus faecalis* (*E. faecalis*) and *Enterococcus faecium* (*E. faecium*). Then we
132 designed different DNA primers targeting selected species-specific DNA tags from each

133 species (**S1 and S2 Table**).

134 To evaluate our primers' specificity in identifying species, we chose *S. aureus* and *S.*
135 *epidermidis* from the same genus as our cross-validated target species. We extracted
136 DNA sequences of the *S. aureus* and the *S. epidermidis* amplified by primers used in
137 FilmArray Pneumonia Panel developed by BioFire and in our protocol, which were
138 acquired from NCBI Reference Prokaryotic Representative genomes. We then aligned
139 *S. aureus*-specific DNA sequences with the representative genome of *S. epidermidis*
140 using blast to search the most similar DNA sequences. In the FilmArray Pneumonia
141 Panel, DNA amplified sequences from the *S. aureus* and the *S. epidermidis* were aligned
142 to each other (two different gene regions, *rpoB* and *gyrB*, were used to separate two
143 species).

144 **2.4. Patients**

145 Patients admitted to ICUs and diagnosed with severe pneumonia were recruited from
146 Aug 27, 2019. The recruit criteria for patients were: (1) age \geq 18 years; (2) had artificial
147 airway and expected to retain for more than 48 hours; (3) clinically diagnosed as
148 pneumonia, and the microbiology of etiology was unclear; (4) signed informed consent;
149 (5) the expected length of staying in ICU was more than 3 days. According to previous
150 mortality acquired from the adequate anti-infective group, the sample size calculation
151 (two-group rate) for patients was done, and a sample size of 73 patients in each group
152 was needed.

153 **2.5. Clinical outcomes**

154 BALFs were obtained from all the patients from 2 groups on day 1, day 3-5, and day 7-

155 10 after recruitment and were sent directly to the hospital diagnostic microbiology
156 laboratory for CCT and susceptibility testing. BALFs from patients of the experiment
157 group were also sent for SSBD tests immediately after sampling. Other clinical records
158 included blood routine tests, CRP and PCT examinations.

159 All enrolled patients received primary empirical antibiotic therapy. Once the SSBD
160 results of the patients in the experiment group were obtained, the decisions about
161 whether antibiotics were adjusted or not were made by two senior doctors according to
162 the SSBD results and other clinical information. While in the control group, adjustment
163 depended on conventional culture results and clinical data. Patient demographics and
164 other vital clinical parameters were recorded. Acute Physiology and Chronic Health
165 Evaluation II (APACHE II) scores and Sequential Organ Failure Assessment (SOFA)
166 scores were calculated and recorded for patients on days 1, 3, 7, 10 and 14 to assess
167 their disease severity and organ function.

168 **2.6. Statistical analysis**

169 The number of improved patients on different clinical indicators of different days was
170 calculated and tested by Fisher's exact test. APACHE II scores and SOFA scores were
171 tested as a series by two-way ANOVA. Different clinical outcomes and TTAT were
172 tested by the Mann-Whitney test.

173 **2.6. Funding support**

174 This study was funded by National Natural Science Foundation of China. The National
175 Key Scientific Instrument and Equipment Development Project. Project number:
176 81927808.

177

178 **3. Results**

179 **3.1. The identification of species-specific DNA fragments**

180 The first step to identify pathogenic bacteria was to figure out the specific genome
181 information of each species. Unlike viruses or animals, bacteria were quite similar
182 between close-related species but sometimes quite different among different strains of
183 one species due to fast evolution and horizontal gene transfer [13-15]. Therefore, the
184 widely-used method to identify bacteria with conserved genes may not be a good choice
185 [16, 17]. We developed an innovative algorithm and designed a workflow to figure out
186 the best DNA tag for each species for diagnostic application based on 1791 microbe
187 genomes from 232 species (**Fig 2A**). The details could be found in the Supplementary
188 Materials.

189 We started from 10 common bacteria contributing to sepsis infection as the initial
190 panel according to local epidemic data from ICU of Drum Tower hospital and previous
191 studies about pathogens in ICU (**S2 Fig**) [18, 19]. To our surprise, bacteria-specific
192 DNA sequences showed a random distribution and turned out to be only 0.3%-4.1% in
193 the whole genomes of 10 bacteria (**Fig 2B and 2C**). Considering the application
194 scenario of ICU with only basic instruments, PCR+CRISPR/Cas12a system was chosen
195 for the following detection. Based on the identified species-specific DNA fragments,
196 related primers and crRNAs (CRISPR RNA) were designed according to each species
197 (**S1 and S2 Table**).

198 **3.2. The establishment of species-specific bacteria detection tool**

199 Briefly, CRISPR/Cas12a with designed crRNA could be activated by its target, which
200 could be told by whether the reporter probe was cleaved and demonstrated signal as
201 previously reported [20].

202 To optimize the working conditions of the detection tool in ICU, multiple
203 experiments were applied to optimize the sample preparation and detection process.
204 With the gradient concentration of DNA templates, we confirmed that the lowest
205 detection limit was 10^{-15} M with PCR amplification and 10^{-8} M without amplification
206 step (**Fig 3B**), which was consistent with previous studies [21]. In addition, 30 minutes'
207 incubation of CRISPR/Cas12a with PCR products was enough to demonstrate signals
208 (**Fig 3B**). An additional purification step right after PCR amplification appeared
209 unnecessary to acquire the positive result but helpful for weaker signal (**S3A Fig**). In
210 addition, the comparison of CRISPR/Cas incubation duration confirmed that
211 fluorescence value showed a significant difference from 5 minutes and reached its
212 maximum after 30 minutes compared to the negative control (**S3B Fig**).

213 To confirm the primary behavior of SSBD, two clinical strains separated from
214 different patients for each of 10 selected bacteria species were collected and tested by
215 SSBD as the positive control, which showed clear positive results (**S3C Fig**). To further
216 confirm the specificity of SSBD, each bacteria strain was tested by 10 SSBD test panels
217 targeting different bacteria. Compared to negative control, only SSBD targeting the
218 tested bacteria showed a positive result, which confirmed its high specificity (**Fig 3C**).

219 Putting these results together, a standard operating procedure was finally established
220 for the following validation stages (**Fig 3A**), which was capable of providing the

221 information about the ten most common pathogenic bacteria in ICU. Since this method
222 was a quite fast and species-specific bacteria detection tool, we named it SSBD.

223 **3.3. The accuracy and clinical benefits of SSBD**

224 We started our study with validation stage I, which was a non-intervention study with
225 77 samples of BALF extracted from patients. Samples were detected both by SSBD
226 and CCT, and the results were compared (raw detection results were shown in **S3 Table**).
227 Generally, 5 of 10 selected bacteria were detected by both tests, including *A. baumannii*,
228 *K. pneumoniae*, *P. aeruginosa*, *S. aureus* and *S. maltophilia*. SSBD could detect those
229 5 bacteria separately with 100% sensitivity and over 87% specificity, which were
230 calculated by the results of CCT as golden standard (**Fig 4A**). The other 5 bacteria were
231 detected by SSBD but not CCT, including *E. coli*, *S. epidermidis*, *S. capitis*, *E. faecalis*
232 and *E. faecium*. To further evaluate the results, 11 samples among all 77 samples were
233 collected randomly and sent for NGS detection, which confirmed that SSBD and NGS
234 demonstrated quite high similarities in results (**Fig 4A**).

235 Based on these accurate results, we started the validation stage II, which was an
236 intervention study aiming to evaluate the clinical benefits of SSBD compared to the
237 current diagnosis and treatment strategy in ICU. Although the study was paused due to
238 the outbreak of SARS-CoV2, 22 patients were recruited into the experiment group and
239 24 patients into the control group. The baseline characteristics had no significant
240 difference except ages (**S5 Table**).

241 We finally got 57 BALF results tested by SSBD, which included 43 results that also
242 had CCT results among them in the experiment group. While in the control group, we

243 got 63 samples tested only by CCT. In the experiment group, 47 samples were positive
244 among 57 samples tested by SSBD, while 28 samples were positive among 43 samples
245 tested by CCT (raw detection results were shown in **S4 Table**). In the control group, 41
246 samples showed positive among 63 samples. It was shown that SSBD could detect each
247 bacterium with similar high sensitivity and specificity in validation stage II (**Fig 4B**).
248 Consistent with the local epidemic data, the most frequent occurrence was *A. baumannii*
249 (**Fig 4B**). 12 of the 57 samples were also sent for the NGS technology, and the SSBD
250 also showed high consistency between those two methods compared to CCT (**Fig 4B**).

251 To explore clinical benefits with the help of SSBD, effective antibiotic coverage rate,
252 APACHE II scores and SOFA scores were calculated and compared to evaluate the
253 rationalization of antibiotic therapy and patients' disease severity and organ function
254 status in the two groups (**Fig 4C-4E**). Effective antibiotic coverage rates for each test
255 were significantly higher in the experimental group than those in the control group in
256 three tests (**Fig 4C**). The definition of antibiotic coverage and the original calculation
257 results were shown in **S4A-B Fig**. APACHE II scores were significantly lower in the
258 experimental group than those in the control group after day 1 ($p=0.0035$, two-way
259 ANOVA); the separation between two groups of patients increased progressively until
260 day 14 (**Fig 4D**). SOFA scores showed no difference between the groups ($p=0.8918$,
261 two-way ANOVA) (**Fig 4E**). Other clinical outcomes showed no significant difference
262 in both groups, such as time of ventilation, shock, 28-day mortality and the numbers of
263 antibiotic-associated diarrhea (**S6 Table**).

264 **3.4. Polymicrobial infection and nosocomial events observed by SSBD**

265 Based on the previous studies, CCT had defects in the evaluation of polymicrobial
266 infection events due to the limitations of its technology [22]. Therefore, we tried to
267 evaluate whether SSBD demonstrated better performance with polymicrobial infection.
268 Here, we defined situations of infection with more than one pathogenic microorganism
269 as polymicrobial infection events to assess the performance based on the results of both
270 methods. From the results, the detection rate of polymicrobial infection events by SSBD
271 was 41.8% (55/134) in two validation stages, which was significantly higher than 11.7%
272 (14/120) of CCT (**Fig 5A**). To confirmed the reliability of the extra detected
273 polymicrobial infection events by SSBD, 6 samples were sent for NGS, which
274 demonstrated the same results as SSBD (**Fig 5B**).

275 Since both SSBD and NGS were based on target DNA, we wanted to confirm if some
276 polymicrobial infection events were “false positive” and caused by dead bacteria. Here,
277 we showed patient B19 as an example, who received three times tests at day 1, 3 and 7
278 by both CCT and SSBD. Based on the results, *S. maltophilia* was detected as level II in
279 test1 with SSBD but not CCT. Later on, *S. maltophilia* was detected by CCT in test2 as
280 well with few days’ development from level II to level III based on result of SSBD,
281 which means SSBD discovered the true polymicrobial infection event earlier than CCT
282 (**Fig 5C**). From the aspect of pathogen species participated in polymicrobial infection
283 events, both methods demonstrated similar results with *A. baumannii*, *S. maltophilia*, *P.*
284 *aeruginosa*, *K. pneumoniae* and *S. aureus* in top 5 (**Fig 5D**), which were consistent with
285 the frequency of pathogens in ICU [18].

286 Hospital infections, also known as nosocomial infections, are an important factor in

287 the incidence rate and mortality of ICU patients with severe pneumonia [23]. Since
288 CCT has a long delay in clinical feedback of pathogenic results, there is no effective
289 monitoring method in clinical practice. Here, we tried to evaluate nosocomial infections
290 based on the test results. We defined a case as a nosocomial infection event if a
291 pathogenic bacterium was newly detected in the current time point but not before. For
292 example, B17 (*K. pneumoniae* at test 2, *E. faecalis* at test 3) and B19 (*S. maltophilia* at
293 test 2, *K. pneumoniae* at test 3) patients were discovered as nosocomial infection cases
294 for SSBD and CCT (**Fig 5E and 5F**). Based on the results of SSBD, 47.6% (10/21) of
295 patients had nosocomial infections at the test 2, and 28.6% (4/14) of patients had
296 nosocomial infections at the test 3. Similarly, 40% (4/10) of patients were identified as
297 nosocomial infections by CCT at test 2, and 27.3% (3/11) of patients were identified as
298 nosocomial infections at test 3 (**Fig 5G**).

299

300 **4. Discussion**

301 In this study, we developed a rapid bacteria detection technique based on
302 CRISPR/Cas12a using species-specific DNA tags and detected common bacteria taken
303 from pneumonia in 4 hours with 100% sensitivity and over 87% specificity in the
304 validation stage I. Currently, there are already some market-oriented detection
305 technologies for pneumonia patients, such as FilmArray Pneumonia Panel by BioFire
306 and Curetis Unyvero system, which also could detect microorganisms in several hours
307 [12]. Sequences used by FilmArray Pneumonia Panel from two gene regions had highly
308 similar DNA sequences in the *S. epidermidis* representative genome (E-value=5e-40,

309 *rpoB*; E-value=8e-39, *gyrB*), which could interfere with pathogen identification
310 between species from the same genus. It was ideal for early and rapid screening of
311 infectious diseases but was not applicable in the ICU, considering the complexity and
312 urgency of infection events within the ICU. We have adopted a completely different
313 strategy from the existing methods, getting specific gene regions from species for
314 further test using our developed bioinformatics workflow and algorithm. It was shown
315 that our sequences used for *S. aureus* diagnosis had no similar fragments in *S.*
316 *epidermidis*, which avoided distinguishing different species by gene diversity. It was
317 likely to get the species-specific DNA tags from such amount genomes when aligned
318 bacterial genomes with each other but consuming computational cost. We optimized
319 calculation processes by rescheduling steps and then made it possible for us to acquire
320 species-specific DNA regions after shortening time to a range bearable.

321 NGS technology is useful in species identification and also shows its advantages in
322 clinical diagnosis. It is valuable to detect uncommon pathogens because of its unique
323 capability in detecting multiple agents across the full microbial spectrum contributing
324 to disease and has already been developed as a new detection platform [9]. However,
325 in the majority of cases of common pathogens, redundant microorganism results were
326 probably unhelpful to the anti-infection regimen. In addition, the high cost and
327 relatively long turnaround time prevent its widespread application, especially in the
328 ICU circumstance. Therefore, our SSBD method seemed more advantageous in time-
329 consuming and information effectiveness than other mentioned methods, especially
330 when we could quantify bacterial load based on fluorescence intensity for better

331 antibiotic therapy strategy. CRISPR/Cas12a and qPCR are both quantitative methods,
332 but CRISPR/Cas12a shows its robustness and lower equipment requirement, which
333 satisfied our needs for most of the ICU. There are still several challenges in
334 implementing POCT in developing countries, especially the qPCR/POCT system,
335 which will be an alternative.

336 The results of SSBD demonstrated high sensitivity and specificity. However, we
337 discovered several “false positive” results compared to CCT, which might be caused by
338 two reasons: 1) The low bacterial load of the patient sample was probably not enough
339 or needed much longer time than expected to be cultivated. SSBD provided a lower
340 threshold of detection (10^{-15} M) than CCT, which could detect pathogens that even
341 existed in trace amounts which unable to be cultivated. In our study, the fluorescence
342 intensity obtained from SSBD was divided into three intervals (level I: 10^{-15} - 10^{-14} M,
343 level II: 10^{-14} M- 10^{-13} M, level III: over 10^{-13} M), representing the different strengths of
344 bacteria (roughly equivalent to bacteria amounts according to our lowest detection
345 thresholds, dividing details in Supplementary Method SSBD diagnostic report and **S4A**
346 **Fig**). All false-positive results were calculated on the count of species and strengths,
347 mostly belonging to the level I or II (**S5 Fig**). Considering most of those false positive
348 samples were also validated by NGS technology, it suggested that some pathogens
349 might be missed in the CCT results. 2) Cultivation could fail in detecting pathogens
350 that failed in competitive growth environments. It was interesting to see that many
351 patients were infected by more than one pathogen, which might cause potential
352 competition between different pathogens in CCT process (**S7 Table**). For example, *A.*

353 *baumannii* was found to be the most competitive bacteria in cultivation, which may be
354 due to its fastest growth rate. On the other hand, *P. aeruginosa* seemed to be relatively
355 the weakest one among them, which was usually concealed in the cultivation with other
356 species existing (sample A16, B19-3, B21-1, B21-2 after we excluded all samples with
357 *A. baumannii* existing).

358 When evaluating the clinical benefit from SSBD, the quicker directed therapy
359 adjustment for patients in the experiment group (Exp: 10.2±8.8 hours vs. Con:
360 96.0±35.1 hours, $p < 0.0001$, Mann-Whitney test) could shorten the empirical anti-
361 infection time and seemed to alleviate illness severity (APACHE II score) during the
362 validation stage II with the help of the SSBD. Some clinical parameters were also
363 showed good tendency in the experiment group patients on day 7, including the absolute
364 value of white blood cell (WBC), the cases number with abnormal body temperature
365 improved, and the clinical anti-infection efficiency (**S6 Table**). It implied that
366 appropriate antibiotic treatment guided by in-time pathogenic information would
367 alleviate acute physiological illness. Nevertheless, at the endpoint, clinical outcomes
368 showed no differences between the two groups, which may due to the insufficient
369 patient numbers.

370 Despite the size in our intervention stage, there were still some aspects that have not
371 been considered. 1) Resistance genes were not included in the study. Multi-drug
372 resistant organisms (MDROs) prevailed in ICU [24, 25], which might not improve the
373 situation of patients even with accurate pathogenic information. There were a few cases
374 (e.g. B07, B25 and B35 patients) showing no signs of clearing the bacterial infection.

375 2) The 10 designed pathogens were originated from sepsis, which might not completely
376 overlap with pathogens of severe pneumonia, though pneumonia is one of the most
377 common causes of sepsis. The panel pathogens could be optimized flexibly for meeting
378 diverse clinical needs in the ICU. 3) Other potential pathogenic microbes, such as
379 viruses and fungus, might affect the clinical outcomes considering the complexity of
380 ICU patients.

381 Previous studies showed that polymicrobial pneumonia is related to an increased risk
382 of inappropriate antimicrobial treatment [26]. In both phases, a total of 55 samples were
383 identified as polymicrobial infections by SSBD, while only 14 samples were identified
384 as polymicrobial infections by CCT, which suggested that SSBD could provide more
385 precise pathogenic bacteria information than CCT, especially for those patients with
386 polymicrobial infections. On the other hand, nosocomial infections contribute to a
387 considerable proportion of deaths in ICU patients with severe pneumonia [23].
388 Although SSBD identified similar ratio of nosocomial infection events with CCT (**Fig**
389 **5G**), SSBD provided more timely information for clinical control and response, which
390 might improve the clinical medication decision in ICU.

391 As anticipated, SSBD performed well with high sensitivity and specificity in rapid
392 pathogens identification, and it reduced TTAT, which was associated with more rapid
393 administration of appropriate antimicrobial therapy in the experiment cases. SSBD also
394 has enormous potential in expanding pathogens from different diseases with much more
395 pathogen genomes concluded. We believe that SSBD is competent in the role of clinical
396 application and able to be applied in more clinical research.

397

398 **References**

- 399 1. Singer M, Deutschman CS, Seymour CW, Shankar-Hari M, Annane D, Bauer M, et al. The
400 Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). *Jama-*
401 *Journal of the American Medical Association*. 2016;315(8):801-10.
- 402 2. Ferrer R, Martinez ML, Goma G, Suarez D, Alvarez-Rocha L, de la Torre MV, et al. Improved
403 empirical antibiotic treatment of sepsis after an educational intervention: the ABISS-
404 Edusepsis study. *Crit Care*. 2018;22(1):167.
- 405 3. Kumar A, Roberts D, Wood KE, Light B, Parrillo JE, Sharma S, et al. Duration of hypotension
406 before initiation of effective antimicrobial therapy is the critical determinant of survival in
407 human septic shock. *Critical Care Medicine*. 2006;34(6):1589-96.
- 408 4. Pulia M, Redwood R. Empiric Antibiotic Prescribing for Suspected Sepsis: A Stewardship
409 Balancing Act. *Am J Med Sci*. 2020;360(6):613-4.
- 410 5. Seymour CW, Gesten F, Prescott HC, Friedrich ME, Iwashyna TJ, Phillips GS, et al. Time to
411 Treatment and Mortality during Mandated Emergency Care for Sepsis. *New England*
412 *Journal of Medicine*. 2017;376(23):2235-44.
- 413 6. Abd El-Aziz NK, Gharib AA, Mohamed EAA, Hussein AH. Real-time PCR versus MALDI-
414 TOF MS and culture-based techniques for diagnosis of bloodstream and pyogenic
415 infections in humans and animals. *J Appl Microbiol*. 2021;130(5):1630-44.
- 416 7. Zhou J, Qian C, Zhao M, Yu X, Kang Y, Ma X, et al. Epidemiology and Outcome of Severe
417 Sepsis and Septic Shock in Intensive Care Units in Mainland China. *Plos One*. 2014;9(9).
- 418 8. Chen H, Yin Y, Gao H, Guo Y, Dong Z, Wang X, et al. Clinical Utility of In-house
419 Metagenomic Next-generation Sequencing for the Diagnosis of Lower Respiratory Tract
420 Infections and Analysis of the Host Immune Response. *Clinical Infectious Diseases*.
421 2020;71:S416-S26.
- 422 9. Wang S, Ai J, Cui P, Zhu Y, Wu H, Zhang W. Diagnostic value and clinical application of
423 next-generation sequencing for infections in immunosuppressed patients with
424 corticosteroid therapy. *Annals of Translational Medicine*. 2020;8(5).
- 425 10. Edin A, Eilers H, Allard A. Evaluation of the Biofire Filmarray Pneumonia panel plus for
426 lower respiratory tract infections. *Infectious Diseases*. 2020;52(7):479-88.
- 427 11. Jamal W, Al Roomi E, AbdulAziz LR, Rotimi VO. Evaluation of Curetis Unyvero, a Multiplex
428 PCR-Based Testing System, for Rapid Detection of Bacteria and Antibiotic Resistance and
429 Impact of the Assay on Management of Severe Nosocomial Pneumonia. *Journal of Clinical*
430 *Microbiology*. 2014;52(7):2487-92.
- 431 12. Trotter AJ, Aydin A, Strinden MJ, O'Grady J. Recent and emerging technologies for the
432 rapid diagnosis of infection and antimicrobial resistance. *Current Opinion in Microbiology*.
433 2019;51:39-45.
- 434 13. Nina Dombrowski , Tom A. Williams , Jiarui Sun, Benjamin J. Woodcroft , Jun-Hoe Lee ,
435 Bui Quang Minh , Christian Rinke & Anja Spang. Undinarchaeota illuminate DPANN
436 phylogeny and the impact of gene transfer on archaeal evolution. *Nature Communication*.
437 2020. 11:3939.
- 438 14. Ilana Lauren Brito. Examining horizontal gene transfer in microbial communities. *Nature*

- 439 Reviews Microbiology. 2021; 19(7): 442-453.
- 440 15. Mathieu Groussin, Mathilde Poyet, Elevated rates of horizontal gene transfer in the
441 industrialized human microbiome. *Cell*. 2021; 184: 2053–2067.
- 442 16. C. Maslunka, V. Gurtler and R.J. Seviour. The impact of horizontal gene transfer on
443 targeting the internal transcribed spacer region (ITS) to identify *Acinetobacter junii* strains.
444 *Journal of Applied Microbiology*. 2015; 118: 1435-1443.
- 445 17. José M. Padial and Ignacio De la Riva. A paradigm shift in our view of species drives current
446 trends in biological classification. *Biol. Rev.* 2021; 96:731-751.
- 447 18. De Pascale G, Bello G, Tumbarello M, Antonelli M: Severe pneumonia in intensive care:
448 cause, diagnosis, treatment and management: a review of the literature. *Current Opinion*
449 *in Pulmonary Medicine* 2012, 18(3):213-221.
- 450 19. Sakr Y, Jaschinski U, Wittebole X, Szakmany T, Lipman J, Namendys-Silva SA, Martin-
451 Loeches I, Leone M, Lupu M-N, Vincent J-L *et al*: Sepsis in Intensive Care Unit Patients:
452 Worldwide Data From the Intensive Care over Nations Audit. *Open Forum Infectious*
453 *Diseases* 2018, 5(12).
- 454 20. Janice S. Chen, Enbo Ma, Lucas B. Harrington, Maria Da Costa, Xinran Tian, Joel M. Palefsky,
455 Jennifer A. Doudna. CRISPR-Cas12a target binding unleashes indiscriminate single-
456 stranded DNase activity. *Science*. 2018;360:436-439.
- 457 21. Jonathan S. Gootenberg, Omar O. Abudayyeh, Max J. Kellner, Julia Joung, James J. Collins,
458 Feng Zhang. Multiplexed and portable nucleic acid detection platform with Cas13, Cas12a,
459 and Csm6. *Science*. 2018;360:439-444.
- 460 22. Andreia S. Azevedo, Carina Almeida, Luís F. Melo & Nuno F. Azevedo. Impact of
461 polymicrobial biofilms in catheter-associated urinary tract infections. *Crit Rev Microbiol*.
462 2016. 43(4):423-439.
- 463 23. Rafael Zaragoza, Pablo Vidal-Cortés, Gerardo Aguilar, Marcio Borges, Emili Diaz, Ricard
464 Ferrer, Emilio Maseda, Mercedes Nieto, Francisco Xavier Nuvials, Paula Ramirez, Alejandro
465 Rodriguez, Cruz Soriano, Javier Véganzones and Ignacio Martín-Loeches. Update of the
466 treatment of nosocomial pneumonia in the ICU. 2020. 24(1):383.
- 467 24. Liu J, Zhang L, Pan J, Huang M, Li Y, Zhang H, et al. Risk Factors and Molecular
468 Epidemiology of Complicated Intra-Abdominal Infections With Carbapenem-Resistant
469 Enterobacteriaceae: A Multicenter Study in China. *J Infect Dis*. 2020;221(Suppl 2):S156-
470 S63.
- 471 25. Yang Q, Zhang H, Yu Y, Kong H, Duan Q, Wang Y, et al. In Vitro Activity of
472 Imipenem/Relebactam Against Enterobacteriaceae Isolates Obtained from Intra-
473 abdominal, Respiratory Tract, and Urinary Tract Infections in China: Study for Monitoring
474 Antimicrobial Resistance Trends (SMART), 2015-2018. *Clin Infect Dis*. 2020;71(Suppl
475 4):S427-S35.
- 476 26. Lisa Karner, Susanne Drechsler, Magdalena Metzger, Ara Hacobian, Barbara Schädli, Paul
477 Slezak, Johannes Grillari and Peter Dungal. Antimicrobial photodynamic therapy fighting
478 polymicrobial infections – a journey from in vitro to in vivo. *Photochemical &*
479 *Photobiological Sciences*. 2020. 19(10):1332-1343.
- 480 27. Carolyn B Ibberson and Marvin Whiteley. The social life of microbes in chronic infection.
481 *Current Opinion in Microbiology*. 2020. 53:44-50.

482

483

484 **Figure Legends**

485

486 **Figure 1: Study Design**

487 This study contained four stages: discovery stage, training stage, validation stage I and
488 validation stage II. All patients were from the Department of Critical Care Medicine,
489 Nanjing Drum Tower Hospital. Patients were randomly divided into two groups for the
490 clinical trial.

491

492 **Figure 2: Screening workflow and statistics of species-specific DNA-tags.**

493 A. Schematic diagram of screening species-specific DNA-tags.

494 B. Genomic distribution of species-specific DNA-tags in 10 bacteria.

495 C. Genomic proportion of species-specific DNA-tags in 10 bacteria.

496

497 **Figure 3: SSBD development and effectiveness validation.**

498 A. SSBD workflow for clinical validation stages.

499 B. Cas12a and Cas12a-after-PCR detection of different concentrations and reaction
500 times including 30 minutes (left) and 60 minutes (right). Blue bars indicated the
501 Cas12a-after-PCR test. Brown bars indicated Cas12a test only. The concentration
502 gradient of pGL3 plasmid from 10^{-17} M- 10^{-7} M was established as the test group.
503 NC stood for the fluorescence values of PCR products of using DEPC-H₂O as input.
504 Each group had three repeats. Error bars indicated mean \pm SEM of fluorescence
505 value. ** indicated p value<0.01 and *** indicated p value<0.001 of unpaired t-test.

506 C. SSBD results of 10 pathogenic bacteria.

507 Every test panel for each of 10 bacteria was used to detect genome DNA samples of 10
508 bacteria by SSBD. NC stood for the fluorescence values of PCR products of using
509 DEPC-H₂O as input. Each group had three repeats. Error bars indicated mean±SEM
510 of fluorescence value.

511

512 **Figure 4: Statistical analysis of test results and clinical outcomes in the two**
513 **validation stages.**

514 A. Cross-tables for 5 of 10 bacteria by both SSBD and CCT and comparative analysis
515 of SSBD, CCT and NGS results in the validation stage I.

516 B. Cross-tables for 5 of 10 bacteria by both SSBD and CCT and comparative analysis
517 of SSBD, CCT and NGS results in the validation stage II.

518 C. Antibiotics coverage rate of each test in the two groups. Exp meant the experimental
519 group, and Con meant the control group. Test 1: Day 1. Test 2: Day 3-5. Test 3: Day 7+.

520 Raw antibiotics coverage results of each patient were available in S2B Fig. Detailed
521 judging guidelines were shown in Supplementary Material.

522 D and E. Line charts for APACHE II and SOFA scores, respectively. Error bars
523 indicated mean±SEM of scores of all the recorded patients. * indicated a significant
524 difference between the two groups using two-way ANOVA.

525

526 **Figure 5: Statistical analysis of polymicrobial infection and nosocomial infection**
527 **in the two validation stages.**

528 A. Statistics of pathogenic infection status of BALF samples in the two validation

529 stages.

530 B. Verification from NGS results for 6 samples identified as polymicrobial infection by

531 SSBD but not CCT.

532 C. Case study of polymicrobial infection detected by SSBD and CCT.

533 D. Statistics of pathogens involved in polymicrobial infections in the two stages.

534 E. Case study of nosocomial infection identified by SSBD.

535 F. Case study of nosocomial infection identified by CCT.

536 G. Percentage of nosocomial infection identified by SSBD and CCT.

537

Fig 1






Fig 2

A



B



C




Fig 3






Fig 4


A Validation Stage I




B Validation Stage II



C



D



E






Fig 5




Supplementary Figure 1




Supplementary Figure 2

Nanjing Drum Tower Hospital (2017)




Supplementary Figure 3



Supplementary Figure 5

A Validation stage I



B Validation stage II

